Patent US2195244A successfully refreshed from Google Patents.
Patent US4156012A successfully refreshed from Google Patents.
US4156012A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-allergic bis phenylene compositions and uses
Assignee: Pharmacia and Upjohn Co
•
Filing: 1977-10-06
•
Granted: 1979-05-22
•
Expires: 1997-10-06
Abstract
Abstract A method of treating mammals for allergy and anaphylactic reactions of a reagin or non-reagin mediated nature which comprises administering prophylactically to said mammal an anti-allergy or anaphylactic reaction effective amount of a compound of the formula ##STR1## Novel compositions are also claimed.
Inventors
- 👤 Charles M. Hall
- 👤 John B. Wright
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 09:00
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/275; A61K31/21; A61K31/215; A61K31/235; A61K31/24; C; C07; C07C; C07C255/00; C07C255/49; C07C255/58
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
148 words
A method for treating a mammal for an allergic condition selected from the group consisting of asthma, rhinitis, food allergy and urticaria which comprises prophylactically administering to a mammal in need of treatment an anti-asthma, anti-rhinitis, anti-food allergy, or anti-urticaria effective amount of a compound of the formula ##STR16## wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation, alkyl of one to six carbon atoms, inclusive, and ##STR17## wherein n is 0, 1 or 2; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR18## with the proviso that when one or both of R 1 and R 2 are ##STR19## groups on a phenylene ring are not ortho to each other; X is --CH 2 ) m wherein m is zero, 1, 2, or 3.
Claim 2
Independent Claim
148 words
A method for treating a mammal for an allergic condition selected from the group consisting of asthma, rhinitis, food allergy and urticaria which comprises prophylactically administering to a mammal in need of treatment an anti-asthma, anti-rhinitis, anti-food allergy, or anti-urticaria effective amount of a compound of the formula ##STR16## wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation, alkyl of one to six carbon atoms, inclusive, and ##STR17## wherein n is 0, 1 or 2; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR18## with the proviso that when one or both of R 1 and R 2 are ##STR19## groups on a phenylene ring are not ortho to each other; X is --CH 2 ) m wherein m is zero, 1, 2, or 3.
Claim 3
Dependent Claim
33 words
A method in accordance with claim 1 wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation and alkyl of one to six carbon atoms, inclusive.
Claim 4
Dependent Claim
69 words
A method in accordance with claim 2 wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation and alkyl of one to three carbon atoms, inclusive; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, cyano and nitro; and X is --CH 2 ) m wherein m is zero or 1.
Claim 5
Dependent Claim
13 words
A method in accordance with claim 1 wherein the compound is diethyl N,N'-(methylene-p-diphenylene)dioxamate.
Claim 6
Dependent Claim
13 words
A method in accordance with claim 1 wherein the compound is N,N'-(methylene-p-diphenylene)dioxamic acid.
Claim 7
Dependent Claim
13 words
A method in accordance with claim 1 wherein the compound is diethyl N,N'-4,4'-biphenylenedioxamate.
Claim 8
Dependent Claim
14 words
A method in accordance with claim 1 wherein the compound is N,N'-4,4'-biphenylene dioxamic acid.
Claim 9
Dependent Claim
119 words
A pharmaceutical composition which comprises an anti-asthma, anti-rhinitis, anti-food allergy, or anti-urticaria effective amount of a compound of the formula ##STR20## wherein R is selected from the group consisting of hydrogen and a physiologically acceptable metal or amine cation, R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR21## with the proviso that when one or both of R 1 and R 2 are ##STR22## groups on a phenylene ring are not ortho to each other; X is selected from the group consisting of --CH 2 ) m wherein m is zero, 1, 2, or 3, in association with a pharmaceutical carrier suitable for inhalation.
Claim 10
Dependent Claim
119 words
A pharmaceutical composition which comprises an anti-asthma, anti-rhinitis, anti-food allergy, or anti-urticaria effective amount of a compound of the formula ##STR20## wherein R is selected from the group consisting of hydrogen and a physiologically acceptable metal or amine cation, R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR21## with the proviso that when one or both of R 1 and R 2 are ##STR22## groups on a phenylene ring are not ortho to each other; X is selected from the group consisting of --CH 2 ) m wherein m is zero, 1, 2, or 3, in association with a pharmaceutical carrier suitable for inhalation.
Claim 11
Dependent Claim
116 words
A pharmaceutical composition which comprises an anti-asthma, anti-rhinitis, anti-food allergy, or anti-urticaria effective amount of a compound of the formula ##STR23## wherein R is selected from the group consisting of hydrogen and a physiologically acceptable metal or amine cation; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR24## with the proviso that when one or both of R 1 and R 2 are ##STR25## groups on a phenylene ring are not ortho to each other; X is selected from the group consisting of --CH 2 ) m wherein m is zero, 1, 2, or 3, in association with a pharmaceutical carrier.
Claim 12
Dependent Claim
116 words
A pharmaceutical composition which comprises an anti-asthma, anti-rhinitis, anti-food allergy, or anti-urticaria effective amount of a compound of the formula ##STR23## wherein R is selected from the group consisting of hydrogen and a physiologically acceptable metal or amine cation; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR24## with the proviso that when one or both of R 1 and R 2 are ##STR25## groups on a phenylene ring are not ortho to each other; X is selected from the group consisting of --CH 2 ) m wherein m is zero, 1, 2, or 3, in association with a pharmaceutical carrier.
Claim 13
Dependent Claim
145 words
A pharmaceutical composition which comprises as the sole active ingredient an anti-allergy or anti-asthma, anti-rhinitis, anti-food allergy, or anti-urticaria effective amount of a compound of the formula ##STR26## wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation, alkyl of one to six carbon atoms, inclusive, and ##STR27## wherein n is 0, 1 or 2; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR28## with the proviso that when one or both of R 1 and R 2 are ##STR29## groups on a phenylene ring are not ortho to each other; X is --CH 2 ) m wherein m ix zero, 1, 2, or 3, in association with a pharmaceutical carrier and in the dosage form of capsule, tablet, or aerosol for inhalation.
Claim 14
Dependent Claim
145 words
A pharmaceutical composition which comprises as the sole active ingredient an anti-allergy or anti-asthma, anti-rhinitis, anti-food allergy, or anti-urticaria effective amount of a compound of the formula ##STR26## wherein R is selected from the group consisting of hydrogen, a physiologically acceptable metal or amine cation, alkyl of one to six carbon atoms, inclusive, and ##STR27## wherein n is 0, 1 or 2; R 1 and R 2 are the same or different and are selected from the group consisting of hydrogen, halogen, nitro, cyano and ##STR28## with the proviso that when one or both of R 1 and R 2 are ##STR29## groups on a phenylene ring are not ortho to each other; X is --CH 2 ) m wherein m ix zero, 1, 2, or 3, in association with a pharmaceutical carrier and in the dosage form of capsule, tablet, or aerosol for inhalation.
References Cited (Backward Citations)
US3639249A
Cited
US3966965A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-05-21 | 1982-11-20 | 1983-05-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-05-21 | 1986-11-20 | 1987-05-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-05-21 | 1990-11-20 | 1991-05-22 | $7700.00 | Window Closed / Lapsed |